4basebio’s half-year results for period ended 30 June 2021 reflect consistent progress towards its main objective of producing GMP-grade synthetic DNA, while at the same time it is building incremental value into the business through product/technology expansion with first commercial sales of its DNA and increasing corporate partnerships. It generated revenues of £0.15m with adjusted pre-tax loss of £2.7m (H1 2021: £1.8m, +45%) and ended the period with £5.6m cash. Despite the expected increase ....
30 Sep 2022
4basebio - Interims demonstrate sustained technological progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
4basebio - Interims demonstrate sustained technological progress
4basebio PLC (4BB:LON) | 945 0 0.0% | Mkt Cap: 121.0m
- Published:
30 Sep 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
13
4basebio’s half-year results for period ended 30 June 2021 reflect consistent progress towards its main objective of producing GMP-grade synthetic DNA, while at the same time it is building incremental value into the business through product/technology expansion with first commercial sales of its DNA and increasing corporate partnerships. It generated revenues of £0.15m with adjusted pre-tax loss of £2.7m (H1 2021: £1.8m, +45%) and ended the period with £5.6m cash. Despite the expected increase ....